|
1
|
Magalhães JE and Sampaio Rocha-Filho PA:
Migraine and cerebrovascular diseases: Epidemiology,
pathophysiological, and clinical considerations. Headache.
58:1277–1286. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zanon Zotin MC, Sveikata L, Viswanathan A
and Yilmaz P: Cerebral small vessel disease and vascular cognitive
impairment: From diagnosis to management. Curr Opin Neurol.
34:246–257. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gottesman RF and Seshadri S: Risk factors,
lifestyle behaviors, and vascular brain health. Stroke. 53:394–403.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nordestgaard LT, Christoffersen M and
Frikke-Schmidt R: Shared risk factors between dementia and
atherosclerotic cardiovascular disease. Int J Mol Sci. 23:97772022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsao CW, Aday AW, Almarzooq ZI, Anderson
CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK,
Buxton AE, et al: Heart disease and stroke statistics-2023 update:
A report from the American heart association. Circulation.
147:e93–e621. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hilkens NA, Casolla B, Leung TW and de
Leeuw FE: Stroke. Lancet. 403:2820–2836. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goldsborough E III, Osuji N and Blaha MJ:
Assessment of cardiovascular disease risk: A 2022 update.
Endocrinol Metab Clin North Am. 51:483–509. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z, Ma L, Liu M, Fan J and Hu S:
Summary of the 2022 report on cardiovascular health and diseases in
China. Chin Med J (Engl). 136:2899–2908. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Zhang H and Zou Z: Changing
profiles of cardiovascular disease and risk factors in China: A
secondary analysis for the Global Burden of Disease Study 2019.
Chin Med J (Engl). 136:2431–2441. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang W, Liu Y, Liu J, Yin P, Wang L, Qi J,
You J, Lin L, Meng S, Wang F, et al: Mortality and years of life
lost of cardiovascular diseases in China, 2005-2020: Empirical
evidence from national mortality surveillance system. Int J
Cardiol. 340:105–112. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yun CW and Lee SH: Enhancement of
functionality and therapeutic efficacy of Cell-based therapy using
mesenchymal stem cells for cardiovascular disease. Int J Mol Sci.
20:9822019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Biasiolo M, Sales G, Lionetti M, Agnelli
L, Todoerti K, Bisognin A, Coppe A, Romualdi C, Neri A and
Bortoluzzi S: Impact of host genes and strand selection on miRNA
and miRNA* expression. PLoS One. 6:e238542011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Due H, Svendsen P, Bødker JS, Schmitz A,
Bøgsted M, Johnsen HE, El-Galaly TC, Roug AS and Dybkær K: miR-155
as a biomarker in B-cell malignancies. Biomed Res Int.
2016:95130372016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen L, Gao D, Shao Z, Zheng Q and Yu Q:
miR-155 indicates the fate of CD4+ T cells. Immunol Lett.
224:40–49. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang X, Zeng X, Shu J, Bao H and Liu X:
MiR-155 enhances phagocytosis of alveolar macrophages through the
mTORC2/RhoA pathway. Medicine (Baltimore). 102:e345922023.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tili E, Croce CM and Michaille JJ:
miR-155: On the crosstalk between inflammation and cancer. Int Rev
Immunol. 28:264–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suofu Y, Wang X, He Y, Li F, Zhang Y,
Carlisle DL and Friedlander RM: Mir-155 knockout protects against
Ischemia/reperfusion-induced brain injury and hemorrhagic
transformation. Neuroreport. 31:235–239. 2020. View Article : Google Scholar
|
|
18
|
Wu L, Pu L and Zhuang Z: miR-155-5p/FOXO3a
promotes pulmonary fibrosis in rats by mediating NLRP3 inflammasome
activation. Immunopharmacol Immunotoxicol. 45:257–267. 2023.
View Article : Google Scholar
|
|
19
|
Cao RY, Li Q, Miao Y, Zhang Y, Yuan W, Fan
L, Liu G, Mi Q and Yang J: The emerging role of MicroRNA-155 in
cardiovascular diseases. Biomed Res Int. 2016:98692082016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen JG, Xu XM, Ji H and Sun B: Inhibiting
miR-155 protects against myocardial ischemia/reperfusion injury via
targeted regulation of HIF-1α in rats. Iran J Basic Med Sci.
22:1050–1058. 2019.PubMed/NCBI
|
|
21
|
Guo J, Liu HB, Sun C, Yan XQ, Hu J, Yu J,
Yuan Y and Du ZM: MicroRNA-155 promotes myocardial
infarction-induced apoptosis by targeting RNA-Binding protein QKI.
Oxid Med Cell Longev. 2019:45798062019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen W, Wang L and Liu Z: MicroRNA-155
influences cell damage in ischemic stroke via TLR4/MYD88 signaling
pathway. Bioengineered. 12:2449–2458. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bai B, Ji Z, Wang F, Qin C, Zhou H, Li D
and Wu Y: CTRP12 ameliorates post-myocardial infarction heart
failure through down-regulation of cardiac apoptosis, oxidative
stress and inflammation by influencing the TAK1-p38 MAPK/JNK
pathway. Inflamm Res. 72:1375–1390. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Z, Liang K, Zou G, Chen X, Shi S,
Wang G, Zhang K, Li K and Zhai S: Inhibition of miR-155 attenuates
abdominal aortic aneurysm in mice by regulating macrophage-mediated
inflammation. Biosci Rep. 38:BSR201714322018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu XY, Fan WD, Fang R and Wu GF:
Regulation of microRNA-155 in endothelial inflammation by targeting
nuclear factor (NF)-κB P65. J Cell Biochem. 115:1928–1936.
2014.PubMed/NCBI
|
|
26
|
Park M, Choi S, Kim S, Kim J, Lee DK, Park
W, Kim T, Jung J, Hwang JY, Won MH, et al: NF-κB-responsive miR-155
induces functional impairment of vascular smooth muscle cells by
downregulating soluble guanylyl cyclase. Exp Mol Med. 51:1–12.
2019.
|
|
27
|
Pena-Philippides JC, Caballero-Garrido E,
Lordkipanidze T and Roitbak T: In vivo inhibition of miR-155
significantly alters post-stroke inflammatory response. J
Neuroinflammation. 13:2872016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Han W, Zhang Y, Zong Y, Tan N,
Zhang Y, Li L, Liu C and Liu L: Soluble epoxide hydrolase inhibitor
t-AUCB ameliorates vascular endothelial dysfunction by influencing
the NF-κB/miR-155-5p/eNOS/NO/IκB Cycle in hypertensive rats.
Antioxidants (Basel). 11:13722022. View Article : Google Scholar
|
|
29
|
Faccini J, Ruidavets JB, Cordelier P,
Martins F, Maoret JJ, Bongard V, Ferrières J, Roncalli J, Elbaz M
and Vindis C: Circulating miR-155, miR-145 and let-7c as diagnostic
biomarkers of the coronary artery disease. Sci Rep. 7:429162017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang YQ, Huang C, Zhang B and Feng YQ:
Association of circulating miR-155 expression level and
inflammatory markers with white coat hypertension. J Hum Hypertens.
34:397–403. 2020. View Article : Google Scholar
|
|
31
|
Zhang H, Chen G, Qiu W, Pan Q, Chen Y,
Chen Y and Ma X: Plasma endothelial microvesicles and their
carrying miRNA-155 serve as biomarkers for ischemic stroke. J
Neurosci Res. 98:2290–2301. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin ZQ: MicroRNA targets and biomarker
validation for diabetes-associated cardiac fibrosis. Pharmacol Res.
174:1059412021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun G, Yan J, Noltner K, Feng J, Li H,
Sarkis DA, Sommer SS and Rossi JJ: SNPs in human miRNA genes affect
biogenesis and function. RNA. 15:1640–1651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tam W: Identification and characterization
of human BIC, a gene on chromosome 21 that encodes a noncoding RNA.
Gene. 274:157–167. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li C, He H, Zhu M, Zhao S and Li X:
Molecular characterisation of porcine miR-155 and its regulatory
roles in the TLR3/TLR4 pathways. Dev Comp Immunol. 39:110–116.
2013. View Article : Google Scholar
|
|
36
|
Rodriguez A, Vigorito E, Clare S, Warren
MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska
EA, et al: Requirement of bic/microRNA-155 for normal immune
function. Science. 316:608–611. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ruggiero T, Trabucchi M, De Santa F, Zupo
S, Harfe BD, McManus MT, Rosenfeld MG, Briata P and Gherzi R: LPS
induces KH-type splicing regulatory protein-dependent processing of
microRNA-155 precursors in macrophages. FASEB J. 23:2898–2908.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
O'Connell RM, Taganov KD, Boldin MP, Cheng
G and Baltimore D: MicroRNA-155 is induced during the macrophage
inflammatory response. Proc Natl Acad Sci USA. 104:1604–1609. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guo Q, Zhang H, Zhang B, Zhang E and Wu Y:
Tumor necrosis factor-alpha (TNF-α) enhances miR-155-Mediated
endothelial senescence by targeting sirtuin1 (SIRT1). Med Sci
Monit. 25:8820–8835. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu Y, Guo G, Zhong Z, Sun L, Liao L, Wang
X, Cao Q and Chen H: Long non-coding RNA FLVCR1-AS1 sponges miR-155
to promote the tumorigenesis of gastric cancer by targeting c-Myc.
Am J Transl Res. 11:793–805. 2019.PubMed/NCBI
|
|
41
|
Huang RS, Hu GQ, Lin B, Lin ZY and Sun CC:
MicroRNA-155 silencing enhances inflammatory response and lipid
uptake in oxidized Low-density Lipoprotein-stimulated human THP-1
macrophages. J Investig Med. 58:961–967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Caballero-Garrido E, Pena-Philippides JC,
Lordkipanidze T, Bragin D, Yang Y, Erhardt EB and Roitbak T: In
Vivo inhibition of miR-155 promotes recovery after experimental
mouse stroke. J Neurosci. 35:12446–12464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bruen R, Fitzsimons S and Belton O:
miR-155 in the resolution of atherosclerosis. Front Pharmacol.
10:4632019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Uva P, Da Sacco L, Del Cornò M,
Baldassarre A, Sestili P, Orsini M, Palma A, Gessani S and Masotti
A: Rat mir-155 generated from the lncRNA Bic is 'hidden' in the
alternate genomic assembly and reveals the existence of novel
mammalian miRNAs and clusters. RNA. 19:365–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thai TH, Calado DP, Casola S, Ansel KM,
Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, et
al: Regulation of the germinal center response by microRNA-155.
Science. 316:604–608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schliesser MG, Claus R, Hielscher T, Grimm
C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, et
al: Prognostic relevance of miRNA-155 methylation in anaplastic
glioma. Oncotarget. 7:82028–82045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Heo I, Joo C, Cho J, Ha M, Han J and Kim
VN: Lin28 mediates the terminal uridylation of let-7 precursor
MicroRNA. Mol Cell. 32:276–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lu C, Chen B, Chen C, Li H, Wang D, Tan Y
and Weng H: CircNr1h4 regulates the pathological process of renal
injury in salt-sensitive hypertensive mice by targeting miR-155-5p.
J Cell Mol Med. 24:1700–1712. 2020. View Article : Google Scholar
|
|
49
|
Pasca S, Jurj A, Petrushev B, Tomuleasa C
and Matei D: MicroRNA-155 implication in M1 polarization and the
impact in inflammatory diseases. Front Immunol. 11:6252020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang J, Cheng C, Yuan X, He JT, Pan QH
and Sun FY: microRNA-155 acts as an oncogene by targeting the tumor
protein 53-induced nuclear protein 1 in esophageal squamous cell
carcinoma. Int J Clin Exp Pathol. 7:602–610. 2014.PubMed/NCBI
|
|
51
|
Li Y, Zhang L, Dong Z, Xu H, Yan L, Wang
W, Yang Q and Chen C: MicroRNA-155-5p promotes tumor progression
and contributes to paclitaxel resistance via TP53INP1 in human
breast cancer. Pathol Res Pract. 220:1534052021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xiao L, Li X, Mu Z, Zhou J, Zhou P, Xie C
and Jiang S: FTO inhibition enhances the antitumor effect of
temozolomide by targeting MYC-miR-155/23a Cluster-MXI1 feedback
circuit in glioma. Cancer Res. 80:3945–3958. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Costinean S, Zanesi N, Pekarsky Y, Tili E,
Volinia S, Heerema N and Croce CM: Pre-B cell proliferation and
lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155
transgenic mice. Proc Natl Acad Sci USA. 103:7024–7029. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nazari-Jahantigh M, Wei Y, Noels H, Akhtar
S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, et
al: MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in
macrophages. J Clin Invest. 122:4190–4202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kurowska-Stolarska M, Alivernini S,
Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Ierna
M, Fraser AR, Stolarski B, et al: MicroRNA-155 as a proinflammatory
regulator in clinical and experimental arthritis. Proc Natl Acad
Sci USA. 108:11193–11198. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang G, Chen JJ, Deng WY, Ren K, Yin SH
and Yu XH: CTRP12 ameliorates atherosclerosis by promoting
cholesterol efflux and inhibiting inflammatory response via the
miR-155-5p/LXRα pathway. Cell Death Dis. 12:2542021. View Article : Google Scholar
|
|
57
|
Jing H, Liu L, Jia Y, Yao H and Ma F:
Overexpression of the long non-coding RNA Oprm1 alleviates
apoptosis from cerebral Ischemia-reperfusion injury through the
Oprm1/miR-155/GATA3 axis. Artif Cells Nanomed Biotechnol.
47:2431–2439. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xue H, Hua LM, Guo M and Luo JM: SHIP1 is
targeted by miR-155 in acute myeloid leukemia. Oncol Rep.
32:2253–2259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Husain K, Villalobos-Ayala K, Laverde V,
Vazquez OA, Miller B, Kazim S, Blanck G, Hibbs ML, Krystal G,
Elhussin I, et al: Apigenin targets MicroRNA-155, enhances SHIP-1
expression, and augments anti-tumor responses in pancreatic cancer.
Cancers (Basel). 14:36132022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Faraoni I, Antonetti FR, Cardone J and
Bonmassar E: miR-155 gene: A typical multifunctional microRNA.
Biochim Biophys Acta. 1792:497–505. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Johansson J, Berg T, Kurzejamska E, Pang
MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P, et
al: MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from
growth inhibition to epithelial-mesenchymal transition, invasion
and metastasis in breast cancer. Oncogene. 32:5614–5624. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jiang D and Aguiar RC: MicroRNA-155
controls RB phosphorylation in normal and malignant B lymphocytes
via the noncanonical TGF-β1/SMAD5 signaling module. Blood.
123:86–93. 2014. View Article : Google Scholar :
|
|
63
|
Li DP, Fan J, Wu YJ, Xie YF, Zha JM and
Zhou XM: MiR-155 up-regulated by TGF-β promotes
epithelial-mesenchymal transition, invasion and metastasis of human
hepatocellular carcinoma cells in vitro. Am J Transl Res.
9:2956–2965. 2017.
|
|
64
|
Ke F, Wang H, Geng J, Jing X, Fang F, Fang
C and Zhang BH: MiR-155 promotes inflammation and apoptosis via
targeting SIRT1 in hypoxic-ischemic brain damage. Exp Neurol.
362:1143172023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhai Y, Liu B, Wu L, Zou M, Mei X and Mo
X: Pachymic acid prevents neuronal cell damage induced by
hypoxia/reoxygenation via miR-155/NRF2/HO-1 axis. Acta Neurobiol
Exp (Wars). 82:197–206. 2022.
|
|
66
|
Zhang W, Wang L, Wang R, Duan Z and Wang
H: A blockade of microRNA-155 signal pathway has a beneficial
effect on neural injury after intracerebral haemorrhage via
reduction in neuroinflammation and oxidative stress. Arch Physiol
Biochem. 128:1235–1241. 2022. View Article : Google Scholar
|
|
67
|
Sun L, Ji S and Xing J: Inhibition of
microRNA-155 alleviates neurological dysfunction following
transient global ischemia and contribution of neuroinflammation and
oxidative stress in the hippocampus. Curr Pharm Des. 25:4310–4317.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yang J, Si D, Zhao Y, He C and Yang P:
S-amlodipine improves endothelial dysfunction via the
RANK/RANKL/OPG system by regulating microRNA-155 in hypertension.
Biomed Pharmacother. 114:1087992019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han
X, Tang D and Chen R: Research progress on the relationship between
atherosclerosis and inflammation. Biomolecules. 8:802018.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zheng B, Yin WN, Suzuki T, Zhang XH, Zhang
Y, Song LL, Jin LS, Zhan H, Zhang H, Li JS and Wen JK:
Exosome-Mediated miR-155 transfer from smooth muscle cells to
endothelial cells induces endothelial injury and promotes
atherosclerosis. Mol Ther. 25:1279–1294. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
González-López P, Ares-Carral C,
López-Pastor AR, Infante-Menéndez J, González Illaness T, Vega de
Ceniga M, Esparza L, Beneit N, Martín-Ventura JL, Escribano Ó and
Gómez-Hernández A: Implication of miR-155-5p and miR-143-3p in the
vascular insulin resistance and instability of human and
experimental atherosclerotic plaque. Int J Mol Sci. 23:102532022.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Gimbrone MA Jr and García-Cardeña G:
Endothelial cell dysfunction and the pathobiology of
atherosclerosis. Circ Res. 118:620–636. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ota H, Eto M, Ogawa S, Iijima K, Akishita
M and Ouchi Y: SIRT1/eNOS axis as a potential target against
vascular senescence, dysfunction and atherosclerosis. J Atheroscler
Thromb. 17:431–435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hong FF, Liang XY, Liu W, Lv S, He SJ,
Kuang HB and Yang SL: Roles of eNOS in atherosclerosis treatment.
Inflamm Res. 68:429–441. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sun HX, Zeng DY, Li RT, Pang RP, Yang H,
Hu YL, Zhang Q, Jiang Y, Huang LY, Tang YB, et al: Essential role
of microRNA-155 in regulating Endothelium-dependent vasorelaxation
by targeting endothelial nitric oxide synthase. Hypertension.
60:1407–1414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhu N, Zhang D, Chen S, Liu X, Lin L,
Huang X, Guo Z, Liu J, Wang Y, Yuan W and Qin Y: Endothelial
enriched microRNAs regulate angiotensin II-induced endothelial
inflammation and migration. Atherosclerosis. 215:286–293. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Lee HJ, Lee EJ and Seo M: Galpha12
protects vascular endothelial cells from serum Withdrawal-induced
apoptosis through regulation of miR-155. Yonsei Med J. 57:247–253.
2016. View Article : Google Scholar :
|
|
78
|
Zhao Y, Rao W, Wan Y, Yang X, Wang G, Deng
J, Dai M and Liu Q: Overexpression of microRNA-155 alleviates
palmitate-induced vascular endothelial cell injury in human
umbilical vein endothelial cells by negatively regulating the Wnt
signaling pathway. Mol Med Rep. 20:3527–3534. 2019.PubMed/NCBI
|
|
79
|
Wei DH, Jia XY, Liu YH, Guo FX, Tang ZH,
Li XH, Wang Z, Liu LS, Wang GX, Jian ZS and Ruan CG: Cathepsin L
stimulates autophagy and inhibits apoptosis of ox-LDL-induced
endothelial cells: Potential role in atherosclerosis. Int J Mol
Med. 31:400–406. 2013. View Article : Google Scholar
|
|
80
|
Hu M, Ladowski JM and Xu H: The role of
autophagy in vascular endothelial cell health and physiology.
Cells. 13:8252024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Jiang X, Ma C, Gao Y, Cui H, Zheng Y, Li
J, Zong W and Zhang Q: Tongxinluo attenuates atherosclerosis by
inhibiting ROS/NLRP3/caspase-1-mediated endothelial cell
pyroptosis. J Ethnopharmacol. 304:1160112023. View Article : Google Scholar
|
|
82
|
Zhang Z, Pan X, Yang S, Ma A, Wang K, Wang
Y, Li T and Liu S: miR-155 Promotes ox-LDL-Induced autophagy in
human umbilical vein endothelial cells. Mediators Inflamm.
2017:91748012017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yin S, Yang S, Pan X, Ma A, Ma J, Pei H,
Dong Y, Li S, Li W and Bi X: MicroRNA-155 promotes ox-LDL-induced
autophagy in human umbilical vein endothelial cells by targeting
the PI3K/Akt/mTOR pathway. Mol Med Rep. 18:2798–2806.
2018.PubMed/NCBI
|
|
84
|
McCully KS: Homocysteine and the
pathogenesis of atherosclerosis. Expert Rev Clin Pharmacol.
8:211–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Witucki Ł and Jakubowski H: Homocysteine
metabolites inhibit autophagy by upregulating miR-21-5p,
miR-155-5p, miR-216-5p, and miR-320c-3p in human vascular
endothelial cells. Sci Rep. 14:71512024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Alonso-Piñeiro JA, Gonzalez-Rovira A,
Sánchez-Gomar I, Moreno JA and Durán-Ruiz MC: Nrf2 and heme
Oxygenase-1 involvement in atherosclerosis related oxidative
stress. Antioxidants (Basel). 10:14632021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Pulkkinen KH, Ylä-Herttuala S and Levonen
AL: Heme oxygenase 1 is induced by miR-155 via reduced BACH1
translation in endothelial cells. Free Radic Biol Med.
51:2124–2131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Gou L, Liu G, Ma R, Regmi A, Zeng T, Zheng
J, Zhong X and Chen L: High fat-induced inflammation in vascular
endothelium can be improved by Abelmoschus esculentus and metformin
via increasing the expressions of miR-146a and miR-155. Nutr Metab
(Lond). 17:352020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yang D, Wang J, Xiao M, Zhou T and Shi X:
Role of Mir-155 in controlling HIF-1α level and promoting
endothelial cell maturation. Sci Rep. 6:353162016. View Article : Google Scholar
|
|
90
|
Frismantiene A, Philippova M, Erne P and
Resink TJ: Smooth muscle cell-driven vascular diseases and
molecular mechanisms of VSMC plasticity. Cell Signal. 52:48–64.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Choi S, Park M, Kim J, Park W, Kim S, Lee
DK, Hwang JY, Choe J, Won MH, Ryoo S, et al: TNF-α elicits
phenotypic and functional alterations of vascular smooth muscle
cells by miR-155-5p-dependent down-regulation of cGMP-dependent
kinase 1. J Biol Chem. 293:14812–14822. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Chen L, Zheng SY, Yang CQ, Ma BM and Jiang
D: MiR-155-5p inhibits the proliferation and migration of VSMCs and
HUVECs in atherosclerosis by targeting AKT1. Eur Rev Med Pharmacol
Sci. 23:2223–2233. 2019.PubMed/NCBI
|
|
93
|
Tong Y, Zhou MH, Li SP, Zhao HM, Zhang YR,
Chen D, Wu YX and Pang QF: MiR-155-5p attenuates vascular smooth
muscle cell oxidative stress and migration via inhibiting BACH1
expression. Biomedicines. 11:16792023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Tang Y, Song H, Shen Y, Yao Y, Yu Y, Wei
G, Long B and Yan W: MiR-155 acts as an inhibitory factor in
atherosclerosis-associated arterial pathogenesis by down-regulating
NoxA1 related signaling pathway in ApoE(-/-) mouse. Cardiovasc
Diagn Ther. 11:1–13. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
He S, Wu C, Xiao J, Li D, Sun Z and Li M:
Endothelial extracellular vesicles modulate the macrophage
phenotype: Potential implications in atherosclerosis. Scand J
Immunol. 87:e126482018. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chistiakov DA, Melnichenko AA, Myasoedova
VA, Grechko AV and Orekhov AN: Mechanisms of foam cell formation in
atherosclerosis. J Mol Med (Berl). 95:1153–1165. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zhang F, Zhao J, Sun D and Wei N: MiR-155
inhibits transformation of macrophages into foam cells via
regulating CEH expression. Biomed Pharmacother. 104:645–651. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Li X, Kong D, Chen H, Liu S, Hu H, Wu T,
Wang J, Chen W, Ning Y, Li Y and Lu Z: miR-155 acts as an
anti-inflammatory factor in atherosclerosis-associated foam cell
formation by repressing calcium-regulated heat stable protein 1.
Sci Rep. 6:217892016. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhu J, Chen T, Yang L, Li Z, Wong MM,
Zheng X, Pan X, Zhang L and Yan H: Regulation of microRNA-155 in
atherosclerotic inflammatory responses by targeting MAP3K10. PLoS
One. 7:e465512012. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ye J, Guo R, Shi Y, Qi F, Guo C and Yang
L: miR-155 Regulated inflammation response by the SOCS1-STAT3-PDCD4
axis in atherogenesis. Mediators Inflamm. 2016:80601822016.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zheng J, Wang W, Hong T, Yang S, Shen J
and Liu C: Suppression of microRNA-155 exerts an anti-inflammatory
effect on CD4+ T cell-mediated inflammatory response in the
pathogenesis of atherosclerosis. Acta Biochim Biophys Sin
(Shanghai). 52:654–664. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Peng Q, Yin R, Zhu X, Jin L, Wang J, Pan X
and Ma A: miR-155 activates the NLRP3 inflammasome by regulating
the MEK/ERK/NF-κB pathway in carotid atherosclerotic plaques in
ApoE(-/-) mice. J Physiol Biochem. 78:365–375. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang Y, Li X, Wang D, Jiang X, Zhang M
and Lv K: Serum exosome microRNA panel as a noninvasive biomarker
for molecular diagnosis of fulminant myocarditis. Mol Ther Methods
Clin Dev. 20:142–151. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Oh JH, Kim GB and Seok H: Implication of
microRNA as a potential biomarker of myocarditis. Clin Exp Pediatr.
65:230–238. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lewandowski P, Goławski M, Baron M,
Reichman-Warmusz E and Wojnicz R: A systematic review of miRNA and
cfDNA as potential biomarkers for liquid biopsy in myocarditis and
inflammatory dilated cardiomyopathy. Biomolecules. 12L:14762022.
View Article : Google Scholar
|
|
106
|
Aleshcheva G, Baumeier C, Harms D, Bock
CT, Escher F and Schultheiss HP: MicroRNAs as novel biomarkers and
potential therapeutic options for inflammatory cardiomyopathy. ESC
Heart Fail. 10:3410–3418. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bao JL and Lin L: MiR-155 and miR-148a
reduce cardiac injury by inhibiting NF-κB pathway during acute
viral myocarditis. Eur Rev Med Pharmacol Sci. 18:2349–2356.
2014.PubMed/NCBI
|
|
108
|
Zhang Y, Zhang M, Li X, Tang Z, Wang X,
Zhong M, Suo Q, Zhang Y and Lv K: Silencing MicroRNA-155 attenuates
cardiac injury and dysfunction in viral myocarditis via promotion
of M2 phenotype polarization of macrophages. Sci Rep. 6:226132016.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Yan L, Hu F, Yan X, Wei Y, Ma W, Wang Y,
Lu S and Wang Z: Inhibition of microRNA-155 ameliorates
experimental autoimmune myocarditis by modulating Th17/Treg immune
response. J Mol Med (Berl). 94:1063–1079. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhang Z, Dai X, Qi J, Ao Y, Yang C and Li
Y: Astragalus mongholicus (Fisch.) bge improves peripheral treg
cell immunity imbalance in the children with viral myocarditis by
reducing the levels of miR-146b and miR-155. Front Pediatr.
6:1392018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Derda AA, Thum S, Lorenzen JM, Bavendiek
U, Heineke J, Keyser B, Stuhrmann M, Givens RC, Kennel PJ, Schulze
PC, et al: Blood-based microRNA signatures differentiate various
forms of cardiac hypertrophy. Int J Cardiol. 196:115–122. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
He W, Huang H, Xie Q, Wang Z, Fan Y, Kong
B, Huang D and Xiao Y: MiR-155 knockout in fibroblasts improves
cardiac remodeling by targeting tumor protein p53-Inducible nuclear
protein 1. J Cardiovasc Pharmacol Ther. 21:423–435. 2016.
View Article : Google Scholar
|
|
113
|
Kelly M, Bagnall RD, Peverill RE, Donelan
L, Corben L, Delatycki MB and Semsarian C: A polymorphic miR-155
binding site in AGTR1 is associated with cardiac hypertrophy in
Friedreich ataxia. J Mol Cell Cardiol. 51:848–854. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
de Oliveira G, Freire PP, Omoto ACM, Cury
SS, Fuziwara CS, Kimura ET, Dal-Pai-Silva M and Carvalho RF:
Osteoglycin post-transcriptional regulation by miR-155 induces
cellular architecture changes in H9c2 cardiomyoblasts. Gene.
676:9–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Yang Y, Zhou Y, Cao Z, Tong XZ, Xie HQ,
Luo T, Hua XP and Wang HQ: miR-155 functions downstream of
angiotensin II receptor subtype 1 and calcineurin to regulate
cardiac hypertrophy. Exp Ther Med. 12:1556–1562. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Seok HY, Chen J, Kataoka M, Huang ZP, Ding
J, Yan J, Hu X and Wang DZ: Loss of MicroRNA-155 protects the heart
from pathological cardiac hypertrophy. Circ Res. 114:1585–1595.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Yu H, Qin L, Peng Y, Bai W and Wang Z:
Exosomes derived from hypertrophic cardiomyocytes induce
inflammation in macrophages via miR-155 mediated MAPK Pathway.
Front Immunol. 11:6060452020. View Article : Google Scholar
|
|
118
|
Wang B, Wang ZM, Ji JL, Gan W, Zhang A,
Shi HJ, Wang H, Lv L, Li Z, Tang T, et al: Macrophage-derived
exosomal Mir-155 regulating cardiomyocyte pyroptosis and
hypertrophy in uremic cardiomyopathy. JACC Basic Transl Sci.
5:148–166. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Wang Y, Feng T, Duan S, Shi Y, Li S, Zhang
X and Zhang L: miR-155 promotes fibroblast-like synoviocyte
proliferation and inflammatory cytokine secretion in rheumatoid
arthritis by targeting FOXO3a. Exp Ther Med. 19:1288–1296.
2020.PubMed/NCBI
|
|
120
|
Fan Y, Liu L, Fang K, Huang T, Wan L, Liu
Y, Zhang S, Yan D, Li G, Gao Y, et al: Resveratrol Ameliorates
cardiac hypertrophy by Down-regulation of miR-155 through
activation of breast cancer type 1 susceptibility protein. J Am
Heart Assoc. 5:e0026482016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Yuan Y, Wang J, Chen Q, Wu Q, Deng W, Zhou
H and Shen D: Long non-coding RNA cytoskeleton regulator RNA
(CYTOR) modulates pathological cardiac hypertrophy through
miR-155-mediated IKKi signaling. Biochim Biophys Acta Mol Basis
Dis. 1865:1421–1427. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Murphy A and Goldberg S: Mechanical
complications of myocardial infarction. Am J Med. 135:1401–1409.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Bentzon JF, Otsuka F, Virmani R and Falk
E: Mechanisms of plaque formation and rupture. Circ Res.
114:1852–1866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wang C, Zhang C, Liu L, A X, Chen B, Li Y
and Du J: Macrophage-Derived mir-155-Containing exosomes suppress
fibroblast proliferation and promote fibroblast inflammation during
cardiac injury. Mol Ther. 25:192–204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Hu J, Huang CX, Rao PP, Zhou JP, Wang X,
Tang L, Liu MX and Zhang GG: Inhibition of microRNA-155 attenuates
sympathetic neural remodeling following myocardial infarction via
reducing M1 macrophage polarization and inflammatory responses in
mice. Eur J Pharmacol. 851:122–132. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Hu J, Huang CX, Rao PP, Cao GQ, Zhang Y,
Zhou JP, Zhu LY, Liu MX and Zhang GG: MicroRNA-155 inhibition
attenuates endoplasmic reticulum stress-induced cardiomyocyte
apoptosis following myocardial infarction via reducing macrophage
inflammation. Eur J Pharmacol. 857:1724492019. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Palatinus JA, Valdez S, Taylor L,
Whisenant C, Selzman CH, Drakos SG, Ranjan R, Hong T, Saffitz JE
and Shaw RM: GJA1-20k rescues Cx43 localization and arrhythmias in
arrhythmogenic cardiomyopathy. Circ Res. 132:744–746. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Yang HT, Li LL, Li SN, Wu JT, Chen K, Song
WF, Zhang GB, Ma JF, Fu HX, Cao S, et al: MicroRNA-155 inhibition
attenuates myocardial infarction-induced connexin 43 degradation in
cardiomyocytes by reducing pro-inflammatory macrophage activation.
Cardiovasc Diagn Ther. 12:325–339. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zhu W, Du W, Duan R, Liu Y, Zong B, Jin X,
Dong Z, Wang H, Shahab S, Wang H, et al: miR-873-5p suppression
reinvigorates aging mesenchymal stem cells and improves cardiac
repair after myocardial infarction. ACS Pharmacol Transl Sci.
7:743–756. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Hong Y, He H, Jiang G, Zhang H, Tao W,
Ding Y, Yuan D, Liu J, Fan H, Lin F, et al: miR-155-5p inhibition
rejuvenates aged mesenchymal stem cells and enhances
cardioprotection following infarction. Aging Cell. 19:e131282020.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Lu Q, Shen Q, Su J, Li X, Xia B and Tang
A: Inhibition of mir-155-5p alleviates cardiomyocyte pyroptosis
induced by hypoxia/reoxygenation via targeting SIRT1-mediated
activation of the NLRP3 inflammasome. J Cardiothorac Surg.
20:1352025. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Zhang H, Ma J, Liu F and Zhang J: Long
non-coding RNA XIST promotes the proliferation of cardiac
fibroblasts and the accumulation of extracellular matrix by
sponging microRNA-155-5p. Exp Ther Med. 21:4772021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Schumacher D, Curaj A, Simsekyilmaz S,
Schober A, Liehn EA and Mause SF: miR155 deficiency reduces
myofibroblast density but fails to improve cardiac function after
myocardial infarction in dyslipidemic mouse model. Int J Mol Sci.
22:54802021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Xie W, Li P, Wang Z, Chen J, Lin Z, Liang
X and Mo Y: Rosuvastatin may reduce the incidence of cardiovascular
events in patients with acute coronary syndromes receiving
percutaneous coronary intervention by suppressing miR-155/SHIP-1
signaling pathway. Cardiovasc Ther. 32:276–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Li X, Liu R, Liu W, Liu X, Fan Z, Cui J,
Wu Y, Yin H and Lin Q: Panax quinquefolium L. and Salvia
miltiorrhiza Bunge. enhances angiogenesis by regulating the
miR-155-5p/HIF-1α/VEGF axis in acute myocardial infarction. Drug
Des Devel Ther. 17:3249–3267. 2023. View Article : Google Scholar :
|
|
136
|
Zhang M, Liu Q, Meng H, Duan H, Liu X, Wu
J, Gao F, Wang S, Tan R and Yuan J: Ischemia-reperfusion injury:
Molecular mechanisms and therapeutic targets. Signal Transduct
Target Ther. 9:122024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Zhang Q, Jia M, Wang Y, Wang Q and Wu J:
Cell death mechanisms in cerebral ischemia-reperfusion injury.
Neurochem Res. 47:3525–3542. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Liu Y, Li L, Wang Z, Zhang J and Zhou Z:
Myocardial ischemia-reperfusion injury; Molecular mechanisms and
prevention. Microvasc Res. 149:1045652023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Eisenhardt SU, Weiss JB, Smolka C,
Maxeiner J, Pankratz F, Bemtgen X, Kustermann M, Thiele JR, Schmidt
Y, Bjoern Stark G, et al: MicroRNA-155 aggravates
ischemia-reperfusion injury by modulation of inflammatory cell
recruitment and the respiratory oxidative burst. Basic Res Cardiol.
110:322015. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Xi J, Li QQ, Li BQ and Li N: miR-155
inhibition represents a potential valuable regulator in mitigating
myocardial hypoxia/reoxygenation injury through targeting BAG5 and
MAPK/JNK signaling. Mol Med Rep. 21:1011–1020. 2020.PubMed/NCBI
|
|
141
|
Huang G, Hao F and Hu X: Downregulation of
microRNA-155 stimulates sevoflurane-mediated cardioprotection
against myocardial ischemia/reperfusion injury by binding to SIRT1
in mice. J Cell Biochem. 120:15494–15505. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Greco R, Demartini C, Zanaboni AM,
Blandini F, Amantea D and Tassorelli C: Endothelial nitric oxide
synthase inhibition triggers inflammatory responses in the brain of
male rats exposed to ischemia-reperfusion injury. J Neurosci Res.
96:151–159. 2018. View Article : Google Scholar
|
|
143
|
Liu M, Fu D, Gao T, Jiang H, Yang P and Li
X: The low expression of miR-155 promotes the expression of SHP2 by
inhibiting the activation of the ERK1/2 pathway and improves cell
pyroptosis induced by I/R in mice. Aging (Albany NY). 16:4778–4788.
2024.PubMed/NCBI
|
|
144
|
Jiang T, Zhou S, Li X, Song J, An T, Huang
X, Ping X and Wang L: MicroRNA-155 induces protection against
cerebral ischemia/reperfusion injury through regulation of the
Notch pathway in vivo. Exp Ther Med. 18:605–613. 2019.PubMed/NCBI
|
|
145
|
Zhang L, Liu C, Huang C, Xu X and Teng J:
miR-155 knockdown protects against cerebral ischemia and
reperfusion injury by targeting MafB. Biomed Res Int.
2020:64582042020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Shi Y, Li K, Xu K and Liu QH: MiR-155-5p
accelerates cerebral ischemia-reperfusion injury via targeting
DUSP14 by regulating NF-κB and MAPKs signaling pathways. Eur Rev
Med Pharmacol Sci. 24:1408–1419. 2020.PubMed/NCBI
|
|
147
|
Shi Y, Li Z, Li K and Xu K: miR-155-5p
accelerates cerebral ischemia-reperfusion inflammation injury and
cell pyroptosis via DUSP14/TXNIP/NLRP3 pathway. Acta Biochim Pol.
69:787–793. 2022.PubMed/NCBI
|
|
148
|
Xue Y, Wang Y, Chen T, Peng L, Wang C, Xue
G and Yu S: DJ-1 regulates astrocyte activation through
miR-155/SHP-1 signaling in cerebral ischemia/reperfusion injury. J
Neurochem. 169:e162302025. View Article : Google Scholar
|
|
149
|
Tanai E and Frantz S: Pathophysiology of
heart failure. Compr Physiol. 6:187–214. 2015. View Article : Google Scholar
|
|
150
|
McMurray JJ and Pfeffer MA: Heart failure.
Lancet. 365:1877–1889. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Mosterd A and Hoes AW: Clinical
epidemiology of heart failure. Heart. 93:1137–1146. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Li J, Su H, Zhu Y, Cao Y and Ma X: ETS2
and microRNA-155 regulate the pathogenesis of heart failure through
targeting and regulating GPR18 expression. Exp Ther Med.
19:3469–3478. 2020.PubMed/NCBI
|
|
153
|
Lin B, Zhao H, Li L, Zhang Z, Jiang N,
Yang X, Zhang T, Lian B, Liu Y, Zhang C, et al: Sirt1 improves
heart failure through modulating the NF-κB p65/microRNA-155/BNDF
signaling cascade. Aging (Albany NY). 13:14482–14498. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Gao L, Li T, Li S, Song Z, Chang Y and
Yuan L: Schisandrin A protects against isoproterenol-induced
chronic heart failure via miR-155. Mol Med Rep. 25:242022.
View Article : Google Scholar
|
|
155
|
Luo Y, Deng X, Chen Q, Cai Y, Bie M, Zhang
Y, Peng L, Yao K, Chen X and Cai H: Up-regulation of miR-155
protects against chronic heart failure by inhibiting HIF-1α. Am J
Transl Res. 15:6425–6436. 2023.
|
|
156
|
Heymans S, Corsten MF, Verhesen W, Carai
P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L,
Wijnands E, et al: Macrophage microRNA-155 promotes cardiac
hypertrophy and failure. Circulation. 128:1420–1432. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Zheng L, Xu CC, Chen WD, Shen WL, Ruan CC,
Zhu LM, Zhu DL and Gao PJ: MicroRNA-155 regulates angiotensin II
type 1 receptor expression and phenotypic differentiation in
vascular adventitial fibroblasts. Biochem Biophys Res Commun.
400:483–488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Shi L and Fleming I: One miR level of
control: microRNA-155 directly regulates endothelial nitric oxide
synthase mRNA and protein levels. Hypertension. 60:1381–1382. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Touyz RM, Alves-Lopes R, Rios FJ, Camargo
LL, Anagnostopoulou A, Arner A and Montezano AC: Vascular smooth
muscle contraction in hypertension. Cardiovasc Res. 114:529–539.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Xu D, Liao R, Wang XX and Cheng Z: Effects
of miR-155 on hypertensive rats via regulating vascular mesangial
hyperplasia. Eur Rev Med Pharmacol Sci. 22:7431–7438.
2018.PubMed/NCBI
|
|
161
|
Lai KN, Leung JCK and Tang SCW: The
renin-angiotensin system. Contrib Nephrol. 170:135–144. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Forrester SJ, Booz GW, Sigmund CD, Coffman
TM, Kawai T, Rizzo V, Scalia R and Eguchi S: Angiotensin II signal
transduction: An update on mechanisms of physiology and
pathophysiology. Physiol Rev. 98:1627–1738. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
DuPont JJ, McCurley A, Davel AP, McCarthy
J, Bender SB, Hong K, Yang Y, Yoo JK, Aronovitz M, Baur WE, et al:
Vascular mineralocorticoid receptor regulates microRNA-155 to
promote vasoconstriction and rising blood pressure with aging. JCI
Insight. 1:e889422016. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Theilig F and Wu Q: ANP-induced signaling
cascade and its implications in renal pathophysiology. Am J Physiol
Renal Physiol. 308:F1047–1055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Vandenwijngaert S, Ledsky CD, Agha O, Wu
C, Hu D, Bagchi A, Domian IJ, Buys ES, Newton-Cheh C and Bloch DB:
MicroRNA-425 and microRNA-155 cooperatively regulate atrial
natriuretic peptide expression and cGMP production. PLoS One.
13:e01966972018. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Stonesifer C, Corey S, Ghanekar S,
Diamandis Z, Acosta SA and Borlongan CV: Stem cell therapy for
abrogating stroke-induced neuroinflammation and relevant secondary
cell death mechanisms. Prog Neurobiol. 158:94–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Putaala J: Ischemic stroke in young
adults. Continuum (Minneap Minn). 26:386–414. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Choi GH, Ko KH, Kim JO, Kim J, Oh SH, Han
IB, Cho KG, Kim OJ, Bae J and Kim NK: Association of miR-34a,
miR-130a, miR-150 and miR-155 polymorphisms with the risk of
ischemic stroke. Int J Mol Med. 38:345–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Xing G, Luo Z, Zhong C, Pan X and Xu X:
Influence of miR-155 on cell apoptosis in rats with ischemic
stroke: Role of the ras homolog enriched in brain (Rheb)/mTOR
pathway. Med Sci Monit. 22:5141–5153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Yang Y, Zhang N, Wang S and Wen Y:
MicroRNA-155 regulates inflammatory response in ischemic cerebral
tissues through autophagy. Curr Neurovasc Res. 15:103–110. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Adly Sadik N, Ahmed Rashed L and Ahmed
Abd-El Mawla M: Circulating miR-155 and JAK2/STAT3 axis in acute
ischemic stroke patients and its relation to Post-ischemic
inflammation and associated ischemic stroke risk factors. Int J Gen
Med. 14:1469–1484. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Huang W, Hong Q, Wang H, Zhu Z and Gong S:
MicroRNA-155 inhibition activates Wnt/β-Catenin signaling to
restore Th17/Treg cell balance and protect against acute ischemic
stroke. eNeuro. 12:ENEURO.0347-24.2024. 2025. View Article : Google Scholar
|
|
173
|
Wang J, Li D, Hou J and Lei H: Protective
effects of geniposide and ginsenoside Rg1 combination treatment on
rats following cerebral ischemia are mediated via microglial
microRNA-155-5p inhibition. Mol Med Rep. 17:3186–3193. 2018.
|
|
174
|
Zhang JK, Li Y, Yu ZT, Jiang JW, Tang H,
Tu GL and Xia Y: OIP5-AS1 inhibits oxidative stress and
inflammation in ischemic stroke through miR-155-5p/IRF2BP2 axis.
Neurochem Res. 48:1382–1394. 2023.
|
|
175
|
Bossone E and Eagle KA: Epidemiology and
management of aortic disease: Aortic aneurysms and acute aortic
syndromes. Nat Rev Cardiol. 18:331–348. 2021. View Article : Google Scholar
|
|
176
|
Spin JM, Li DY, Maegdefessel L and Tsao
PS: Non-coding RNAs in aneurysmal aortopathy. Vascul Pharmacol.
114:110–121. 2019. View Article : Google Scholar
|
|
177
|
Hu J, Huang S, Liu X, Zhang Y, Wei S and
Hu X: miR-155: An important role in inflammation response. J
Immunol Res. 2022:74372812022. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Yang X, Peng J, Pang J, Wan W and Chen L:
A functional polymorphism in the promoter region of miR-155
predicts the risk of intracranial hemorrhage caused by rupture
intracranial aneurysm. J Cell Biochem. 120:18618–18628. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Feng Z, Zhang X, Li L, Wang C, Feng M,
Zhao K, Zhao R, Liu J and Fang Y: Tumor-associated
macrophage-derived exosomal microRNA-155-5p stimulates intracranial
aneurysm formation and macrophage infiltration. Clin Sci (Lond).
133:2265–2282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Zhang RL, Wang WM, Li JQ, Li RW, Zhang J,
Wu Y and Liu Y: The role of miR-155 in cardiovascular diseases:
Potential diagnostic and therapeutic targets. Int J Cardiol
Cardiovasc Risk Prev. 24:2003552025.PubMed/NCBI
|
|
181
|
Yang WW, Li QX, Wang F, Zhang XR, Zhang
XL, Wang M, Xue D, Zhao Y and Tang L: Exosomal miR-155-5p promote
the occurrence of carotid atherosclerosis. J Cell Mol Med.
28:e701872024. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Eshraghi R, Rafiei M, Hadian Jazi Z,
Shafie D, Raisi A and Mirzaei H: MicroRNA-155 and exosomal
microRNA-155: Small pieces in the cardiovascular diseases puzzle.
Pathol Res Pract. 257:1552742024. View Article : Google Scholar
|
|
183
|
Kazimierczyk E, Eljaszewicz A, Zembko P,
Tarasiuk E, Rusak M, Kulczynska-Przybik A, Lukaszewicz-Zajac M,
Kaminski K, Mroczko B, Szmitkowski M, et al: The relationships
among monocyte subsets, miRNAs and inflammatory cytokines in
patients with acute myocardial infarction. Pharmacol Rep. 71:73–81.
2019. View Article : Google Scholar
|
|
184
|
Fitzsimons S, Oggero S, Bruen R, McCarthy
C, Strowitzki MJ, Mahon NG, Ryan N, Brennan EP, Barry M, Perretti
M, et al: microRNA-155 is decreased during atherosclerosis
regression and is increased in urinary extracellular vesicles
during atherosclerosis progression. Front Immunol. 11:5765162020.
View Article : Google Scholar
|
|
185
|
Obradovic D, Rommel KP, Blazek S, Klingel
K, Gutberlet M, Lücke C, Büttner P, Thiele H, Adams V, Lurz P, et
al: The potential role of plasma miR-155 and miR-206 as circulatory
biomarkers in inflammatory cardiomyopathy. ESC Heart Fail.
8:1850–1860. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Yao R, Ma Y, Du Y, Liao M, Li H, Liang W,
Yuan J, Ma Z, Yu X, Xiao H and Liao Y: The altered expression of
inflammation-related microRNAs with microRNA-155 expression
correlates with Th17 differentiation in patients with acute
coronary syndrome. Cell Mol Immunol. 8:486–495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Wang Q, Liu L, Chen X, Wang T, Zhou H,
Huang H, Qing L and Luo P: Noninvasive prognosis of postmyocardial
infarction using urinary miRNA ultratrace detection based on
Single-Target DNA-functionalized AuNPs. ACS Appl Mater Interfaces.
14:3633–3642. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Tijsen AJ, Pinto YM and Creemers EE:
Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res.
93:573–582. 2012. View Article : Google Scholar
|
|
189
|
Ikitimur B, Cakmak HA, Coskunpinar E,
Barman HA and Vural VA: The relationship between circulating
microRNAs and left ventricular mass in symptomatic heart failure
patients with systolic dysfunction. Kardiol Pol. 73:740–746. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Ding H, Wang Y, Hu L, Xue S, Wang Y, Zhang
L, Zhang Y, Qi H, Yu H, Aung LHH, et al: Combined detection of
miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217
for screening of early heart failure diseases. Biosci Rep.
40:BSR201916532020. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Kin K, Miyagawa S, Fukushima S, Shirakawa
Y, Torikai K, Shimamura K, Daimon T, Kawahara Y, Kuratani T and
Sawa Y: Tissue- and plasma-specific MicroRNA signatures for
atherosclerotic abdominal aortic aneurysm. J Am Heart Assoc.
1:e0007452012. View Article : Google Scholar
|
|
192
|
Biros E, Moran CS, Wang Y, Walker PJ,
Cardinal J and Golledge J: microRNA profiling in patients with
abdominal aortic aneurysms: The significance of miR-155. Clin Sci
(Lond). 126:795–803. 2014. View Article : Google Scholar
|
|
193
|
Mashima R: Physiological roles of miR-155.
Immunology. 145:323–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Seto AG, Beatty X, Lynch JM, Hermreck M,
Tetzlaff M, Duvic M and Jackson AL: Cobomarsen, an oligonucleotide
inhibitor of miR-155, co-ordinately regulates multiple survival
pathways to reduce cellular proliferation and survival in cutaneous
T-cell lymphoma. Br J Haematol. 183:428–444. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Anastasiadou E, Seto AG, Beatty X,
Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L,
Marchese C, Avigan D, et al: Cobomarsen, an oligonucleotide
inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in
vivo. Clin Cancer Res. 27:1139–1149. 2021. View Article : Google Scholar :
|
|
196
|
Yan Q, Chen J, Li W, Bao C and Fu Q:
Targeting miR-155 to treat experimental scleroderma. Sci Rep.
6:203142016. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Tian FJ, An LN, Wang GK, Zhu JQ, Li Q,
Zhang YY, Zeng A, Zou J, Zhu RF, Han XS, et al: Elevated
microRNA-155 promotes foam cell formation by targeting HBP1 in
atherogenesis. Cardiovasc Res. 103:100–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Tokgozoglu L and Kayikcioglu M: Familial
hypercholesterolemia: Global burden and approaches. Curr Cardiol
Rep. 23:1512021. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X
and Liao YH: MicroRNA-155 modulates Treg and Th17 cells
differentiation and Th17 cell function by targeting SOCS1. PLoS
One. 7:e460822012. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Zhao L, Ouyang Y, Bai Y, Gong J and Liao
H: miR-155-5p inhibits the viability of vascular smooth muscle cell
via targeting FOS and ZIC3 to promote aneurysm formation. Eur J
Pharmacol. 853:145–152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Ertl HCJ: Immunogenicity and toxicity of
AAV gene therapy. Front Immunol. 13:9758032022. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Kahil N, Abouzeinab NS, Hussein MAA and
Khalil MI: Intraperitoneal hepatorenal toxicity of zinc oxide and
nickel oxide nanoparticles in rats: A systematic review.
Nanotoxicology. 18:583–598. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Wei Y, Yan X, Yan L, Hu F, Ma W, Wang Y,
Lu S, Zeng Q and Wang Z: Inhibition of microRNA-155 ameliorates
cardiac fibrosis in the process of angiotensin II-induced cardiac
remodeling. Mol Med Rep. 16:7287–7296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Tang H, Mao J, Ye X, Zhang F, Kerr WG,
Zheng T and Zhu Z: SHIP-1, a target of miR-155, regulates
endothelial cell responses in lung fibrosis. FASEB J. 34:2011–2023.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Kalkusova K, Taborska P, Stakheev D and
Smrz D: The role of miR-155 in antitumor immunity. Cancers (Basel).
14:54142022. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Ghoumari AM, Rixe O, Yarovoi SV, Zerrouqi
A, Mouawad R, Poynard T, Opolon P, Khayat D and Soubrane C: Gene
transfer in hepatocarcinoma cell lines: In vitro optimization of a
virus-free system. Gene Ther. 3:483–490. 1996.PubMed/NCBI
|
|
207
|
Wu J, Wu GY and Zern MA: The prospects of
hepatic drug delivery and gene therapy. Expert Opin Investig Drugs.
7:1795–1817. 1998. View Article : Google Scholar
|
|
208
|
Golubovic A, Tsai S and Li B: Bioinspired
lipid nanocarriers for RNA delivery. ACS Bio Med Chem Au.
3:114–136. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Xu F, Reiser M, Yu X, Gummuluru S, Wetzler
L and Reinhard BM: Lipid-mediated targeting with membrane-wrapped
nanoparticles in the presence of corona formation. ACS Nano.
10:1189–1200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Streeter SS, Hebert KA, Bateman LM, Ray
GS, Dean RE, Geffken KT, Resnick CT, Austin DC, Bell JE, Sparks MB,
et al: Current and future applications of fluorescence guidance in
orthopaedic surgery. Mol Imaging Biol. 25:46–57. 2023. View Article : Google Scholar :
|
|
211
|
Brillante S, Volpe M and Indrieri A:
Advances in MicroRNA therapeutics: From preclinical to clinical
studies. Hum Gene Ther. 35:628–648. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Miao Y, Fu C, Yu Z, Yu L, Tang Y and Wei
M: Current status and trends in small nucleic acid drug
development: Leading the future. Acta Pharm Sin B. 14:3802–3817.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Nappi F: Non-coding RNA-targeted therapy:
A state-of-the-Art review. Int J Mol Sci. 25:36302024. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Vermeire S, Nitcheu J, Gineste P, Flatres
A, Santo J, Scherrer D, Peyrin-Biroulet L, Dulai PS, Danese S,
Dubinsky M, et al: Obefazimod in patients with moderate-to-severely
active ulcerative colitis: Efficacy and safety analysis from the
96-week open-label maintenance phase 2b study. J Crohns Colitis.
19:jjaf0742025. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Bauersachs J, Solomon SD, Anker SD,
Antorrena-Miranda I, Batkai S, Viereck J, Rump S, Filippatos G,
Granzer U, Ponikowski P, et al: Efficacy and safety of CDR132L in
patients with reduced left ventricular ejection fraction after
myocardial infarction: Rationale and design of the HF-REVERT trial.
Eur J Heart Fail. 26:674–682. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem
S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A,
Zhou Y, et al: Treatment of HCV infection by targeting microRNA. N
Engl J Med. 368:1685–1694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Hong DS, Kang YK, Borad M, Sachdev J,
Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, et al: Phase 1
study of MRX34, a liposomal miR-34a mimic, in patients with
advanced solid tumours. Br J Cancer. 122:1630–1637. 2020.
View Article : Google Scholar : PubMed/NCBI
|
